People

Matthias Samwer

ArrePath board member and Boehringer Ingelheim Venture Fund investment manager in the United States. Joined BIVF in 2026 after a decade of drug discovery and oncology R&D at Boehringer Ingelheim. Holds a biology PhD from the Max Planck Institute for Multidisciplinary Sciences, with postdoctoral research at IMBA in Vienna.